ReviewBiomicrofluidics2022
The impact of microfluidics in high-throughput drug-screening applications.
Review in Biomicrofluidics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- High-throughput droplet screening of filamentous fungi on solid substrates.RSC chemical biology · 2026Article
- Reversibly-sealable microfluidic platform for multi-molecule gradient delivery to large adherent cell cultures.Biomedical microdevices · 2026Article
- Vacuum-enhanced high-resolution 3D printing yields 11 200 valves and uniform 7 μm isoporous membranes.Lab on a chip · 2026Article
- Engineering skin microphysiological systems for transdermal drug screening based on strategic model selection and quantitative prediction roadmaps.Materials today. Bio · 2026Review
- Cutting-edge advances in endocrine therapy for breast cancer (Review).Oncology letters · 2026Review
- AI-integrated microfluidics for drug screening: From single cell to organ-on-a-chip.Acta pharmaceutica Sinica. B · 2026Review
- Development of synovial sarcoma organoids exhibiting ferroptosis resistance despite low malic enzyme 1 expression.Scientific reports · 2025Article
- Primary Human Tissue Models for Metabolic Dysfunction-Associated Liver Disease - toward Streamlining Drug Discovery with Patient-Derived Assays.Advanced biology · 2025Review
- Navigating Transition Metal-Dependent Cell Death: Mechanisms, Crosstalk, and Future Directions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Exploring fungal survival mechanisms: toward next-generation antifungal therapies against Candida spp.Archives of microbiology · 2025Review
- Advancements and Future Perspectives of Microfluidic Technology in Pediatric Healthcare.Smart medicine · 2025Review
- Machine-Learning-Aided Advanced Electrochemical Biosensors.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Integrating bioengineering, super-resolution microscopy and mechanobiology in autophagy research: addendum to the guidelines (4th edition).Autophagy · 2025Article
- Cancer Organoids as reliable disease models to drive clinical development of novel therapies.Journal of experimental & clinical cancer research : CR · 2024Article
- Periodic Flows in Microfluidics.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Review
- Drosophila CASK regulates brain size and neuronal morphogenesis, providing a genetic model of postnatal microcephaly suitable for drug discovery.Neural development · 2023Article
- Recent Advances on Cell Culture Platforms for In Vitro Drug Screening and Cell Therapies: From Conventional to Microfluidic Strategies.Advanced healthcare materials · 2023Review
- PSC-derived intestinal organoids with apical-out orientation as a tool to study nutrient uptake, drug absorption and metabolism.Frontiers in molecular biosciences · 2023Article
- Advances in BBB on Chip and Application for Studying Reversible Opening of Blood-Brain Barrier by Sonoporation.Micromachines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Drug discovery is an expensive and lengthy process. Among the different phases, drug discovery and preclinical trials play an important role as only 5-10 of all drugs that begin preclinical tests proceed to clinical trials. Indeed, current high-throughput screening technologies are very expensive, as they are unable to dispense small liquid volumes in an accurate and quick way. Moreover, despite being simple and fast, drug screening assays are usually performed under static conditions, thus failing to recapitulate tissue-specific architecture and biomechanical cues present
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.